Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.

• Váldodahkkit: Walter R J Taylor (Dahkki), Niamh Meagher (Dahkki), Benedikt Ley (Dahkki), Kamala Thriemer (Dahkki), Germana Bancone (Dahkki), Ari Satyagraha (Dahkki), Ashenafi Assefa (Dahkki), Krisin Chand (Dahkki), Nguyen Hoang Chau (Dahkki), Mehul Dhorda (Dahkki), Tamiru S Degaga (Dahkki), Lenny L Ekawati (Dahkki), Asrat Hailu (Dahkki), Mohammad Anwar Hasanzai (Dahkki), Mohammad Nader Naddim (Dahkki), Ayodhia Pitaloka Pasaribu (Dahkki), Awab Ghulam Rahim (Dahkki), Inge Sutanto (Dahkki), Ngo Viet Thanh (Dahkki), Nguyen Thi Tuyet-Trinh (Dahkki), Naomi Waithira (Dahkki), Adugna Woyessa (Dahkki), Arjen Dondorp (Dahkki), Lorenz von Seidlein (Dahkki), Julie A Simpson (Dahkki), Nicholas J White (Dahkki), J Kevin Baird (Dahkki), Nicholas P Day (Dahkki), Ric N Price (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Public Library of Science (PLoS), 2023-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

<h4>Background</h4>The World Health Organization recommends that primaquine should be given once weekly for 8-weeks to patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) deficiency, but data on its antirelapse efficacy and safety are limited.<h4>Met...